Mesenchymal stem cell therapy: bronchopulmonary dysplasia and haemorrhage (Medipost)(Mesenchymal stem cell therapy: bronchopulmonary dysplasia and haemorrhage (Medipost))

概要

基本信息

药物类型

间充质干细胞疗法

别名

Human umbilical cord bloodderived mesenchymal stem cells Medipost、Promostem

靶点-

作用方式-

作用机制

细胞替代物

治疗领域

遗传病与畸形呼吸系统疾病其他疾病

在研适应症-

非在研适应症

支气管肺发育不良出血

原研机构

MEDIPOST Co., Ltd.

在研机构-

非在研机构

MEDIPOST Co., Ltd.

Samsung Medical Center

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 Mesenchymal stem cell therapy: bronchopulmonary dysplasia and haemorrhage (Medipost) 相关的临床试验

NCT04954534

/ Unknown statusN/AIIT

Exploratory Efficacy Study of NEUROSTEM® in Subjects Who Control Group of NEUROSTEM® Phase-I/IIa Clinical Trial

This study is to evaluate of Exploratory Efficacy of NEUROSTEM® in Subjects who control group of NEUROSTEM® Phase-I/IIa Clinical Trial

开始日期2021-07-12

申办/合作机构

Samsung Medical Center

[+1]

NCT03172117

/ Completed临床1/2期

Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.

A long-term follow-up study to obtain safety and efficacy data in subjects who completed phase 1/2a clinical trial of NEUROSTEM® (NCT02054208), comparing NEUROSTEM and placebo groups for up to 36 months after the initial administration in patients suffering from Alzheimer's disease

开始日期2017-05-19

申办/合作机构

MEDIPOST Co., Ltd.

NCT02054208

/ Completed临床1/2期

A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM® Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease

This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived mesenchymal stem cells) versus placebo via an Ommaya reservoir at 4 week intervals in patients with Alzheimer's disease.

开始日期2014-03-01

申办/合作机构

MEDIPOST Co., Ltd.

100 项与 Mesenchymal stem cell therapy: bronchopulmonary dysplasia and haemorrhage (Medipost) 相关的临床结果

登录后查看更多信息

100 项与 Mesenchymal stem cell therapy: bronchopulmonary dysplasia and haemorrhage (Medipost) 相关的转化医学

登录后查看更多信息

100 项与 Mesenchymal stem cell therapy: bronchopulmonary dysplasia and haemorrhage (Medipost) 相关的专利（医药）

登录后查看更多信息

100 项与 Mesenchymal stem cell therapy: bronchopulmonary dysplasia and haemorrhage (Medipost) 相关的药物交易

登录后查看更多信息